Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$2.21 -1.8%	$1.46	$0.46 ▼ $7.49	$12.03M	-0.1	20.90 million shs	410,269 shs
CRDL Cardiol Therapeutics	$1.09 -2.7%	$1.30	$0.77 ▼ $2.63	$93.76M	1.05	1.40 million shs	940,932 shs
CXF CI Canadian Convertible Bond ETF Common	C$10.55 +1.6%	C$10.30	C$9.72 ▼ C$10.61	C$53.33M	N/A	4,243 shs	22,500 shs
IPA ImmunoPrecise Antibodies	$2.49 -6.0%	$1.81	$0.27 ▼ $3.25	$122.31M	0.49	1.68 million shs	1.36 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	-10.00%	+77.17%	+39.75%	+144.57%	-25.50%
CRDL Cardiol Therapeutics	-2.61%	-3.45%	-26.80%	-10.40%	-41.97%
CXF CI Canadian Convertible Bond ETF Common	+1.17%	+0.39%	+0.58%	+2.77%	+4.85%
IPA ImmunoPrecise Antibodies	-3.64%	-8.30%	+31.19%	+361.51%	+245.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	0.5434 of 5 stars	0.0	2.0	0.0	0.0	3.4	1.7	0.0
CRDL Cardiol Therapeutics	2.356 of 5 stars	3.7	2.0	0.0	0.0	3.4	0.0	0.6
CXF CI Canadian Convertible Bond ETF Common	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	2.1184 of 5 stars	3.5	3.0	0.0	0.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	633.94% Upside
CXF CI Canadian Convertible Bond ETF Common	0.00	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	60.64% Upside

Current Analyst Ratings Breakdown

Latest CXF, IPA, APM, and CRDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	27.50	N/A	N/A	$2.20 per share	1.00
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
CXF CI Canadian Convertible Bond ETF Common	N/A	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	$17.59M	6.53	N/A	N/A	$0.37 per share	6.73

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	∞	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	-232.26%	-158.19%	11/13/2025 (Estimated)
CXF CI Canadian Convertible Bond ETF Common	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	-$21.69M	-$0.68	N/A	N/A	-122.10%	-40.62%	-22.19%	9/15/2025 (Estimated)

Latest CXF, IPA, APM, and CRDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/15/2025	Q1 2026	IPA ImmunoPrecise Antibodies	-$0.04	N/A	N/A	N/A	$5.90 million	N/A
8/14/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	-$0.07	+$0.04	-$0.07	N/A	N/A
7/29/2025	Q4 2025	IPA ImmunoPrecise Antibodies	-$0.02	-$0.04	-$0.02	-$0.04	$7.89 million	$5.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
CXF CI Canadian Convertible Bond ETF Common	C$0.48	4.55%	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
CRDL Cardiol Therapeutics	0.01	2.46	2.46
CXF CI Canadian Convertible Bond ETF Common	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	0.49	2.08	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
CRDL Cardiol Therapeutics	12.49%
CXF CI Canadian Convertible Bond ETF Common	N/A
IPA ImmunoPrecise Antibodies	6.70%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
CRDL Cardiol Therapeutics	5.25%
CXF CI Canadian Convertible Bond ETF Common	N/A
IPA ImmunoPrecise Antibodies	6.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
CRDL Cardiol Therapeutics	20	83.71 million	79.32 million	Not Optionable
CXF CI Canadian Convertible Bond ETF Common	90	5.05 million	N/A	Not Optionable
IPA ImmunoPrecise Antibodies	80	46.15 million	43.00 million	Not Optionable

CXF, IPA, APM, and CRDL Headlines

Recent News About These Companies

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

August 27 at 8:22 AM | businesswire.com

Immunoprecise Antibodies Ltd News (IPA) - Investing.com

August 24, 2025 | investing.com

Short Interest in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Grows By 46.3%

August 21, 2025 | marketbeat.com

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe ...

August 6, 2025 | dutchnews.nlD

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate ...

August 6, 2025 | gurufocus.com

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate ...

August 6, 2025 | gurufocus.com

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

August 6, 2025 | financialpost.comF

Short Interest in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Expands By 114.5%

August 6, 2025 | marketbeat.com

ImmunoPrecise (IPA) Q4 2025 Earnings Transcript

August 4, 2025 | fool.com

HC Wainwright Has Positive Outlook for IPA FY2028 Earnings

August 4, 2025 | marketbeat.com

Wall Street Zen Upgrades ImmunoPrecise Antibodies (NASDAQ:IPA) to "Hold"

August 3, 2025 | marketbeat.com

HC Wainwright Has Negative Outlook of IPA Q1 Earnings

August 2, 2025 | marketbeat.com

ImmunoPrecise Antibodies (NASDAQ:IPA) Issues Earnings Results

July 30, 2025 | marketbeat.com

IPA interactive stock chart | ImmunoPrecise Antibodies Ltd. stock - Yahoo Finance

July 29, 2025 | nz.finance.yahoo.com

ImmunoPrecise Antibodies Reports Record Revenue and Growth

July 29, 2025 | tipranks.com

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates

July 29, 2025 | zacks.com

ImmunoPrecise Antibodies Reports Record Fiscal Year 2025 Results

July 29, 2025 | tipranks.com

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

July 29, 2025 | businesswire.com

ImmunoPrecise Unveils Breakthrough in Predicting Drug Antibody Risks

July 24, 2025 | tipranks.com

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

July 24, 2025 | businesswire.com

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

July 16, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CXF, IPA, APM, and CRDL Company Descriptions

Aptorum Group NASDAQ:APM

$2.21 -0.04 (-1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$2.17 -0.04 (-1.81%)

As of 07:59 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Cardiol Therapeutics NASDAQ:CRDL

$1.09 -0.03 (-2.68%)

Closing price 04:00 PM Eastern

Extended Trading

$1.11 +0.02 (+1.83%)

As of 07:44 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

CI Canadian Convertible Bond ETF Common TSE:CXF

C$10.55 +0.17 (+1.64%)

As of 03:53 PM Eastern

The investment objectives of First Asset Canadian Convertible Bond ETF are to provide holders with (i) quarterly cash distributions, and (ii) the opportunity for capital appreciation by investing on a capitalization weighted basis in a portfolio (the Convertible Portfolio) of Convertible Bonds of Canadian issuers. The Convertible ETF will invest on a capitalization weighted basis in Convertible Bonds which meet the Eligibility Criteria. Capitalization weightings are determined on the basis of a Convertible Bonds relative market capitalization to the total market capitalization of Convertible Bonds included in the Convertible Portfolio, on initial investment and on quarterly rebalancings.

ImmunoPrecise Antibodies NASDAQ:IPA

$2.49 -0.16 (-6.04%)

Closing price 04:00 PM Eastern

Extended Trading

$2.48 -0.01 (-0.40%)

As of 07:57 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time